WO2011152689A2 - Method for purifying fucoxanthin derived from seaweed - Google Patents
Method for purifying fucoxanthin derived from seaweed Download PDFInfo
- Publication number
- WO2011152689A2 WO2011152689A2 PCT/KR2011/004103 KR2011004103W WO2011152689A2 WO 2011152689 A2 WO2011152689 A2 WO 2011152689A2 KR 2011004103 W KR2011004103 W KR 2011004103W WO 2011152689 A2 WO2011152689 A2 WO 2011152689A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fucoxanthin
- brown algae
- present
- seaweed
- vitamin
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to a method for purifying fucoxanthin from seaweed, and more particularly, to a method for providing more stabilized fucoxanthine using vitamin C, which is a water-soluble antioxidant, in the process of extracting fuoxanthin from brown algae. .
- fucoxanthin is a unique carotenoid found abundantly in brown algae and has been reported to have an anti-obesity effect (K. Miyashita, Lipid Technology, August / September 2009, Vol. 21, No. 8/9). .
- Fucoxanthine's anti-obesity mechanism induces the expression of uncoupling protein 1 (UCP 1) in the white adipose tissue (WAT) mitochondria, resulting in fatty acid oxidation and heat production in WAT, resulting in fat cell apoptosis ( apoptosis) action.
- UCP 1 uncoupling protein 1
- UCP 1 is a key molecule in the anti-obesity effect. Expression of UCP 1 is known as an important factor of body energy consumption, and obesity is likely to occur when UCP 1 causes dysfunction.
- UCP 1 was expressed in 0.2% fucoxanthin-supplied mouse WAT, but little UCP 1 was expressed in control mouse WAT.
- mRNA of UCP 1 was expressed in 0.2% fucoxanthin-supplied mouse WAT, but mRNA of UCP 1 was hardly expressed in control mouse WAT.
- Fucoxanthin is known to be obtained by extracting, separating and purifying from brown algae by acetone extraction or hexane extraction.
- fucoxanthin due to the high antioxidant properties of fucoxanthin, there is a problem that fucoxanthin is gradually destroyed over time, the fucoxanthin yield is lowered during extraction and purification.
- an object of the present invention is to solve the problem that the fucoxanthin is destroyed over time due to the high antioxidant properties of fucoxanthin, resulting in a decrease in yield.
- the object of the present invention is to provide a more stabilized fucoxanthin by using a water-soluble antioxidant vitamin C in the process of extracting fucoxanthin from brown algae.
- the present invention relates to a method for the separation and purification of fucoxanthin, more specifically
- It relates to a method for purifying fucoxanthin comprising the step of concentrating the obtained fucoxanthin fraction to remove alcohol and then removing water using a nonpolar organic solvent.
- the present invention may optionally include the step of adding tocopherol or cyclodextrin weight ratio 1: 1 to the fucoxanthin obtained by extraction.
- the antioxidants of fucoxanthine have an excellent effect of increasing the viscosity and improving the physical properties of the cosmetics.
- 'algae' refers to brown algae, for example, seaweed ( Undaria pinnatifida ), kelp ( Laminaria ), ⁇ ( Hjijika fusiforme ), and guran ( Sargassum fulvellum).
- Brown algae in the present invention is preferably seaweed.
- the lowest photosynthetic radiation and seawater temperatures during March, April, and May sunshine increase the formation of zeaxanthin to fucoxanthin, making brown algae harvested in March, April, and May. Preferred in terms of xanthine content.
- fresh brown algae are preferred.
- Brown algae are scalded in boiling water to remove salts and enzymes. After that, wash with running water and cool again to remove salt. After washing, remove the water.
- Vitamin C used in the present invention may be any of those used in the art, preferably in powder form. Vitamin C is used in an amount of 0.1 to 5.0% by weight of brown algae, preferably 1 g of vitamin C per kg of brown algae is used. Vitamin C encapsulates fat-soluble fucoxanthin and stabilizes fucoxanthin by oxidizing vitamin C itself first.
- extraction refers to supercritical extraction by immersion in an organic solvent such as ethanol or methanol or using CO 2 .
- an organic solvent obtained by mixing hexane and ethanol in a weight ratio of 3: 7 is preferable for removing chlorophyll, and hexane is preferable for separating water.
- tocopherol may be added to the extracted fucoxanthin to improve storage stability.
- fucoxanthin and the same amount of tocopherol are preferably added.
- Centrifugal Partition Chromatography (CPC) and High Pressure Liquid Chromatography (HPLC) can then be performed to obtain high purity (eg 95%) of fucoxanthine.
- cyclodextrin may be added to the extracted fucoxanthin to realize commercialization with improved viscosity and physical properties.
- fucoxanthin is mixed with the same amount of cyclodextrin, i.e., weight ratio 1: 1, and homogenized with vigorous or gradual pressure.
- the cut samples were extracted at 25 ° C. three times for 2 hours using 3 L of 99% ethanol. After adding the organic solvent mixed with hexane and ethanol at a weight ratio of 3: 7 to the primary extract repeatedly extracted three times, shake the mixture well, and then separate and remove chlorophyll three times. made. Again, a tertiary extract was prepared by removing ethanol from the secondary extract using a vacuum evaporator at 80 ° C. and 200 bar. After adding hexane to the tertiary extract and shaking well to separate the fucoxanthin fraction, the fraction was removed again using a vacuum evaporator. This gave about 5% fucoxanthine (d.w.) concentrate.
- Fucoxanthine samples obtained according to the extraction method were analyzed by the following HPLC analysis conditions.
- the final extract identified as the fucoxanthin fraction was purified using CPC (Centrifugal partition chromatography) over primary and secondary, and fucoxanthin having a purity of 95% or more was extracted (Table 1).
- the fucoxanthin stabilized by the method of the present invention can be used to produce an anti-obesity functional food or an anti-obesity functional cosmetics, which is a very useful invention in the cosmetic and processed food industries.
Abstract
The present invention relates to a method for providing more stabilized fucoxanthin by using vitamin C, which is a water-soluble antioxidizing agent, in the step of extracting fucoxanthin from brown alga. According to the present invention, fucoxanthin is more stabilized, and thus the problem of the deterioration of yield with time is improved.
Description
본 발명은 해조류로부터 푸코산틴(fucoxanthin)의 정제 방법에 관한 것으로, 더욱 구체적으로는 갈조류로부터 푸로산틴을 추출하는 과정에서 수용성 항산화제인 비타민 C를 사용하여 보다 안정화된 푸코산틴을 제공하는 방법에 관한 것이다.The present invention relates to a method for purifying fucoxanthin from seaweed, and more particularly, to a method for providing more stabilized fucoxanthine using vitamin C, which is a water-soluble antioxidant, in the process of extracting fuoxanthin from brown algae. .
최근, 해조류에 포함된 성분이 인체 건강에 유익하다는 연구 결과가 보고되고 있다. 특히, 푸코산틴 성분은 갈조류에서 풍부하게 발견되는 특유의 카로티노이드로, 항-비만 효과를 갖는 것으로 보고되고 있다(K. Miyashita, Lipid Technology, August/September 2009, Vol. 21, No. 8/9). Recently, research results have been reported that ingredients contained in seaweed are beneficial to human health. In particular, fucoxanthin is a unique carotenoid found abundantly in brown algae and has been reported to have an anti-obesity effect (K. Miyashita, Lipid Technology, August / September 2009, Vol. 21, No. 8/9). .
푸코산틴의 항-비만 메커니즘은 백색 체지방(white adipose tissue: WAT) 미토콘드리아에서 탈 결합 단백질 1(uncoupling protein 1: UCP 1)의 발현을 유도하여 WAT에서 지방산 산화 및 열 생성을 일으킴으로써 지방 세포 아포토시스(apoptosis) 작용을 일으키는 것을 특징으로 한다. Fucoxanthine's anti-obesity mechanism induces the expression of uncoupling protein 1 (UCP 1) in the white adipose tissue (WAT) mitochondria, resulting in fatty acid oxidation and heat production in WAT, resulting in fat cell apoptosis ( apoptosis) action.
UCP 1은 항-비만 효과에 있어 핵심 분자이다. UCP 1의 발현은 신체 에너지 소모의 중요 요소로 알려져 있고, UCP 1이 기능 장애를 일으킬 경우에 비만이 발생하기 쉽다. UCP 1 is a key molecule in the anti-obesity effect. Expression of UCP 1 is known as an important factor of body energy consumption, and obesity is likely to occur when UCP 1 causes dysfunction.
푸코산틴과 UCP 1 발현의 관련성을 나타내는 실험 및 그 실험 결과가 상기 문헌에 개시되어 있다. 상기 실험에서, 마우스는 13% 대두 오일(대조군), 12.5% 대두 오일+0.5% 미역속(Undaria) 지질(푸코산틴(Fuco): 0.05%) 및 11% 대두 오일+2% 미역속 지질(Fuco: 0.2%)을 섭취하였다. 도 1에서 알 수 있는 바와 같이, 0.2% 푸코산틴-공급된 마우스 WAT에서는 UCP 1이 발현되었으나, 대조군 마우스 WAT에서는 UCP 1이 거의 발현되지 않았다. 또한, 0.2% 푸코산틴-공급된 마우스 WAT에서는 UCP 1의 mRNA가 발현되었으나, 대조군 마우스 WAT에서는 UCP 1의 mRNA가 거의 발현되지 않았다. 이러한 연구 결과로부터, 푸코산틴이 WAT에서 UCP 1의 단백질 및 mRNA 발현을 유도한다는 것을 알 수 있다.Experiments showing the relationship between fucoxanthin and UCP 1 expression and their experimental results are disclosed in this document. In this experiment, mice received 13% soybean oil (control), 12.5% soybean oil + 0.5% Undaria lipids (Fucoxanthin (Fuco): 0.05%) and 11% soybean oil + 2% brown rice lipids (Fuco : 0.2%) was taken. As can be seen in FIG. 1, UCP 1 was expressed in 0.2% fucoxanthin-supplied mouse WAT, but little UCP 1 was expressed in control mouse WAT. In addition, mRNA of UCP 1 was expressed in 0.2% fucoxanthin-supplied mouse WAT, but mRNA of UCP 1 was hardly expressed in control mouse WAT. These findings indicate that fucoxanthin induces the expression of UCP 1 protein and mRNA in WAT.
이는 푸코산틴의 구조적 특징, 즉, 푸코산틴 대사물질인 푸코산틴올(fucoxanthinol) 및 아마로우시아산틴(amarouciaxanthin) A의 측쇄 기 위에 있는 부가적인 하이드록시 치환기 및 알렌 결합에 기인한 것으로 보인다(H. Maeda, Molecular Medicine Reports 2: 897-902, 2009; 및 K. Miyashita, 상동).This appears to be due to the structural characteristics of fucoxanthin, ie, additional hydroxy substituents and allene bonds on the side chain groups of the fucoxanthin metabolites, fucoxanthinol and amaurociaxanthin A (H Maeda, Molecular Medicine Reports 2: 897-902, 2009; and K. Miyashita, homologous).
푸코산틴은 갈조류로부터 아세톤 추출법이나 헥세인 추출법으로 추출하여 분리, 정제함으로써 수득할 수 있다고 알려져 있다. 그러나, 종래 방법으로 푸코산틴을 추출할 경우, 푸코산틴의 높은 항산화성으로 인해, 시간이 지날수록 푸코산틴이 점차 파괴되고, 추출, 정제 시에 푸코산틴 수율이 떨어지는 문제점이 있었다. Fucoxanthin is known to be obtained by extracting, separating and purifying from brown algae by acetone extraction or hexane extraction. However, in the case of extracting fucoxanthin by the conventional method, due to the high antioxidant properties of fucoxanthin, there is a problem that fucoxanthin is gradually destroyed over time, the fucoxanthin yield is lowered during extraction and purification.
이러한 문제점을 극복하기 위하여, 당업계에서는 미역 시료에 회분을 처리함으로써 색소를 안정화 또는 고정화하려는 시도가 있었다(Bull. Korean Fish Soc. 3(2)). 또한, 일본에 소재하는 오리자 오일 앤드 팻 케미칼 캄파니(Oriza oil & Fat chemical co.)는 지용성 항산화제인 토코페롤을 사용하여 토코페롤이 먼저 산화되도록 함으로써 푸코산틴을 보호하거나, 또는 사이클로덱스트린을 사용하여 푸코산틴을 캡슐화함으로써 푸코산틴을 보호하도록 하였다. 그러나, 이러한 종래 기술에 의해서는 푸코산틴의 안정화가 만족스러운 수준에 이르지 못하였다.In order to overcome this problem, there have been attempts in the art to stabilize or immobilize the pigments by treating ash with seaweed samples (Bull. Korean Fish Soc. 3 (2)). Oriza Oil & Fat Chemical Co., Japan, also protects fucoxanthin by oxidizing tocopherols first using a fat-soluble antioxidant tocopherol, or by using cyclodextrins. Fucoxanthin is protected by encapsulating xanthine. However, this prior art has not reached a satisfactory level of stabilization of fucoxanthin.
따라서, 본 발명의 목적은 푸코산틴의 높은 항산화성으로 인해 시간 경과에 따라 푸코산틴이 파괴되고, 그 결과 수율이 감소되는 문제점을 해결하고자 한다.Therefore, an object of the present invention is to solve the problem that the fucoxanthin is destroyed over time due to the high antioxidant properties of fucoxanthin, resulting in a decrease in yield.
본 발명 상기 목적은 갈조류로부터 푸코산틴을 추출하는 과정에서 수용성 항산화제인 비타민 C를 사용함으로써 보다 안정화된 푸코산틴을 제공하는 데 있다. The object of the present invention is to provide a more stabilized fucoxanthin by using a water-soluble antioxidant vitamin C in the process of extracting fucoxanthin from brown algae.
본 발명의 방법에 의해 푸코산틴을 추출하는 경우, 푸코산틴이 보다 안정화되어 시간 경과에 따른 수율 저하의 문제점을 해결할 수 있는 뛰어난 효과가 있다.In the case of extracting fucoxanthin by the method of the present invention, there is an excellent effect that the fucoxanthin is more stabilized to solve the problem of yield decrease over time.
도 1은 푸코산틴-공급된 마우스 WAT에서의 UCP 1 발현 결과를 나타낸다. 1 shows the results of UCP 1 expression in fucoxanthin-fed mouse WAT.
도 2는 본 발명에 따라 푸코산틴의 HPLC 결과를 나타낸 그래프이다.2 is a graph showing the HPLC results of fucoxanthin according to the present invention.
본 발명은 푸코산틴의 분리정제 방법에 관한 것으로, 보다 구체적으로는The present invention relates to a method for the separation and purification of fucoxanthin, more specifically
갈조류로부터 푸코산틴의 분리과정에서 그의 중량 기준으로 0.1 내지 5.0%의 비타민 C를 첨가하여 혼합하는 단계;Adding and mixing 0.1 to 5.0% of vitamin C based on its weight in the process of separating fucoxanthin from brown algae;
유기 용매를 사용하여 상기 갈조류로부터 엽록소를 추출 제거하는 단계; 및Extracting and removing chlorophyll from the brown algae using an organic solvent; And
수득된 푸코산틴 분획물을 농축하여 알코올을 제거한 후, 비극성 유기용매를 사용하여 물을 제거하는 단계를 포함하는 푸코산틴의 정제 방법에 관한 것이다. It relates to a method for purifying fucoxanthin comprising the step of concentrating the obtained fucoxanthin fraction to remove alcohol and then removing water using a nonpolar organic solvent.
또한, 본 발명은 추출 수득된 푸코산틴에 토코페롤 또는 사이클로덱스트린 중량비 1:1로 첨가하는 단계를 선택적으로 포함할 수 있다. 이렇게 하는 경우에는 푸코산틴의 항산화를 유지할 뿐 아니라 점도를 증가시키고 화장료의 물성을 개선하는 뛰어난 효과가 있었다.In addition, the present invention may optionally include the step of adding tocopherol or cyclodextrin weight ratio 1: 1 to the fucoxanthin obtained by extraction. In this case, not only did the antioxidants of fucoxanthine have an excellent effect of increasing the viscosity and improving the physical properties of the cosmetics.
본 발명에서 ‘갈조류’라 함은 갈색을 띄는 해조류를 말하며, 예컨대, 미역(Undaria pinnatifida), 다시마(Laminaria), 톳(Hijikia fusiforme), 모자반(Sargassum fulvellum) 등을 들 수 있다. 본 발명에서 갈조류는 바람직하게는 미역이다. 또한, 3, 4, 5월 일조 동안에 광합성-활성의 복사선 및 해수 온도가 가장 낮아서, 갈조류 중 제아산틴(zeaxanthin)의 푸코산틴으로의 형성이 증가하므로, 3, 4, 5월에 채취한 갈조류가 푸코산틴 함량 측면에서 바람직하다. 또한, 1년생 갈조류가 바람직하다.In the present invention, 'algae' refers to brown algae, for example, seaweed ( Undaria pinnatifida ), kelp ( Laminaria ), 톳 ( Hjijika fusiforme ), and halban ( Sargassum fulvellum). Brown algae in the present invention is preferably seaweed. The lowest photosynthetic radiation and seawater temperatures during March, April, and May sunshine increase the formation of zeaxanthin to fucoxanthin, making brown algae harvested in March, April, and May. Preferred in terms of xanthine content. Also, fresh brown algae are preferred.
갈조류는 끓는 물에 데쳐서 염분 및 효소를 제거한다. 이후, 흐르는 물로 씻어서 식히면서 다시 염분을 제거한다. 세척 후에는 물기를 제거한다.Brown algae are scalded in boiling water to remove salts and enzymes. After that, wash with running water and cool again to remove salt. After washing, remove the water.
본 발명에서 사용되는 비타민 C는 당업계에서 사용되는 임의의 것일 수 있으며, 바람직하게는 분말 상태이다. 비타민 C는 갈조류의 중량 기준으로 0.1 내지 5.0%의 양으로 사용되고, 바람직하게는 갈조류 1kg당 1g의 비타민 C가 사용된다. 비타민 C는 지용성 푸코산틴을 캡슐화(capsulating)하고, 비타민 C 자신이 먼저 산화함으로써 푸코산틴을 안정화시킨다.Vitamin C used in the present invention may be any of those used in the art, preferably in powder form. Vitamin C is used in an amount of 0.1 to 5.0% by weight of brown algae, preferably 1 g of vitamin C per kg of brown algae is used. Vitamin C encapsulates fat-soluble fucoxanthin and stabilizes fucoxanthin by oxidizing vitamin C itself first.
본 발명에서 ‘추출’이라 함은 에탄올, 메탄올 등의 유기 용매에 침지시키거나 CO2를 이용한 초임계 추출을 의미한다.In the present invention, the term "extraction" refers to supercritical extraction by immersion in an organic solvent such as ethanol or methanol or using CO 2 .
본 발명에서 사용되는 추출 용매로는, 엽록소를 제거하기 위해서는 헥세인 및 에탄올을 3:7의 중량비로 혼합한 유기 용매가 바람직하고, 물을 분리하기 위해서는 헥세인이 바람직하다.As the extraction solvent used in the present invention, an organic solvent obtained by mixing hexane and ethanol in a weight ratio of 3: 7 is preferable for removing chlorophyll, and hexane is preferable for separating water.
그리고, 추출된 푸코산틴에 토코페롤을 첨가하여 보관상의 안정화를 향상시킬 수 있다. 이때, 바람직하게는 푸코산틴과 동량의 토코페롤을 첨가한다. 이어서, 원심분리 분배 크로마토그래피(Centrifugal Partition Chromatography: CPC), 고압 액체 크로마토그래피(HPLC)를 실시하여 고 순도(예컨대, 95%)의 푸코산틴을 수득할 수 있었다. In addition, tocopherol may be added to the extracted fucoxanthin to improve storage stability. In this case, fucoxanthin and the same amount of tocopherol are preferably added. Centrifugal Partition Chromatography (CPC) and High Pressure Liquid Chromatography (HPLC) can then be performed to obtain high purity (eg 95%) of fucoxanthine.
이에 더하여, 추출된 푸코산틴에 사이클로덱스트린을 첨가하여 점성과 물성이 개선된 제품화를 실현할 수 있다. 이 때, 푸코산틴과 동량의 사이클로덱스트린 즉 중량비 1:1로 혼합하여 격렬히 또는 서서히 압력을 가하면서 균질화한다. In addition, cyclodextrin may be added to the extracted fucoxanthin to realize commercialization with improved viscosity and physical properties. At this time, fucoxanthin is mixed with the same amount of cyclodextrin, i.e., weight ratio 1: 1, and homogenized with vigorous or gradual pressure.
본 발명은 하기의 구체적인 실시예에 의해 더욱 상세히 설명되지만, 본 발명이 하기 실시예에 의해 한정되는 것은 아니다.The present invention is explained in more detail by the following specific examples, but the present invention is not limited by the following examples.
실시예: 푸코산틴의 추출 및 정제 Example Extraction and Purification of Fucoxanthin
시료 준비Sample Preparation
3, 4, 5월에 채취한 1년생 갈조류 1kg를 준비하였다. 갈조류를 끓는 물에 5분간 데쳐서, 염분을 제거하고, 갈조류에 존재하는 효소를 실활시켰다. 이어서, 흐르는 물로 잘 씻어서 식히며, 남아있는 염분을 제거하였다. 세척 후에 물기를 제거하였다. 이어서, 수용성 항산화제인 분말 상태의 1g의 비타민 C 를 골고루 뿌린 후에 잘 섞어서 갈조류 시료를 준비하였다. 시료는 5mm 간격으로 절단하였다.1 kg of annual brown algae collected in March, April and May were prepared. Brown algae were boiled in boiling water for 5 minutes to remove salt and deactivate the enzyme present in brown algae. It was then washed well with running water to cool and the remaining salts were removed. Drained after washing. Subsequently, evenly sprayed with 1 g of vitamin C in powder form, which is a water-soluble antioxidant, was mixed well to prepare a brown algae sample. Samples were cut at 5 mm intervals.
추출extraction
상기 절단된 시료를, 99% 에탄올 3L을 사용하여 2시간씩 3차례에 걸쳐 25℃에서 추출하였다. 3차에 걸쳐 반복 추출된 1차 추출물에 헥세인과 에탄올을 3:7의 중량비로 섞은 유기 용매를 첨가한 후에 잘 흔든 후에 엽록소를 분리 제거하는 과정을 3차에 걸쳐 반복 실시하여서 2차 추출물을 만들었다. 다시 80℃, 200bar에서 진공 증발기를 사용하여 상기 2차 추출물에서 에탄올을 제거함으로써 3차 추출물을 만들었다. 상기 3차 추출물에 헥세인을 넣고 잘 흔들어서 푸코산틴 분획물을 분리한 후, 이 분획물을 다시 진공 증발기를 사용하여 헥세인을 제거하였다. 이로부터 약 5%의 푸코산틴(d.w.)농축물을 수득하였다.The cut samples were extracted at 25 ° C. three times for 2 hours using 3 L of 99% ethanol. After adding the organic solvent mixed with hexane and ethanol at a weight ratio of 3: 7 to the primary extract repeatedly extracted three times, shake the mixture well, and then separate and remove chlorophyll three times. made. Again, a tertiary extract was prepared by removing ethanol from the secondary extract using a vacuum evaporator at 80 ° C. and 200 bar. After adding hexane to the tertiary extract and shaking well to separate the fucoxanthin fraction, the fraction was removed again using a vacuum evaporator. This gave about 5% fucoxanthine (d.w.) concentrate.
분석analysis
상기 추출방법에 따라 수득한 푸코산틴 시료를 하기 HPLC 분석조건에 의하여 분석하였다.Fucoxanthine samples obtained according to the extraction method were analyzed by the following HPLC analysis conditions.
colume：YMC corotenoid S3 (1.6×100)colume ： YMC corotenoid S 3 (1.6 × 100)
Flow rate: 1ml/min Flow rate: 1ml / min
Movile phase A: MeOH : MTBE (10:90), B: MeOH : H2O (95:5)Movile phase A: MeOH: MTBE (10:90), B: MeOH: H 2 O (95: 5)
Gradient condition : 0min = B -100% Gradient condition: 0min = B -100%
45min = B - 30% (10min, B-17.5%) 45min = B-30% (10min, B-17.5%)
50min = B - 30% 50min = B-30%
55min = B - 100% 55min = B-100%
carotenoid detection = 445nm carotenoid detection = 445nm
injection volume = 10mL injection volume = 10 mL
상기 조건에 따라 HPLC를 수행한 결과 최종 농축물 중에 푸코산틴이 존재함을 확인하였다(도 2).HPLC was performed according to the above conditions and it was confirmed that fucoxanthin was present in the final concentrate (FIG. 2).
정제refine
상기 푸코산틴 분획물로 확인된 최종 추출물을 1차 및 2차에 걸친 CPC(Centrifugal partition chromatography)를 이용하여 정제한 결과, 95%이상의 순도를 갖는 푸코산틴을 추출하였다(표 1).The final extract identified as the fucoxanthin fraction was purified using CPC (Centrifugal partition chromatography) over primary and secondary, and fucoxanthin having a purity of 95% or more was extracted (Table 1).
표 1 
Table 1
본 발명의 방법에 의해 보다 안정화된 푸코산틴을 이용하여 항-비만 기능성 식품 또는 항-비만 기능성 화장품을 제조할 수 있으므로 화장품 및 가공식품산업상 매우 유용한 발명이다. The fucoxanthin stabilized by the method of the present invention can be used to produce an anti-obesity functional food or an anti-obesity functional cosmetics, which is a very useful invention in the cosmetic and processed food industries.
Claims (2)
- 3~5월 중 채취한 1년생 갈조류에 그의 중량 기준으로 0.1 내지 5.0%의 비타민 C를 첨가하여 혼합하는 단계;Adding to 0.1% to 5.0% of vitamin C by weight based on the weight of annual fresh brown algae collected in March to May;유기 용매를 사용하여 상기 갈조류로부터 엽록소를 추출 제거하는 단계; 및Extracting and removing chlorophyll from the brown algae using an organic solvent; And상기에서 수득된 푸코산틴 분획물을 농축하여 알코올을 제거한 후에, 비극성 유기용매를 사용하여 물을 제거하는 단계를 포함하는 것을 특징으로 하는 안정화된 푸코산틴의 정제 방법. A method for purifying stabilized fucoxanthin comprising the step of removing the alcohol by concentrating the obtained fucoxanthin fraction and then using a nonpolar organic solvent.
- 청구항 1에 있어서,The method according to claim 1,상기 수득된 푸코산틴에 동량의 토코페롤 또는 사이클로덱스트린을 첨가하는 단계를 추가로 더 포함하는 것을 특징으로 하는 안정화된 푸코산틴의 정제 방법.The method for purifying stabilized fucoxanthin further comprising the step of adding the same amount of tocopherol or cyclodextrin to the fucoxanthin obtained.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100052513 | 2010-06-03 | ||
| KR10-2010-0052513 | 2010-06-03 | ||
| KR1020110053920A KR20110133000A (en) | 2010-06-03 | 2011-06-03 | A method for purifying fucoxanthin from seaweeds |
| KR10-2011-0053920 | 2011-06-03 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO2011152689A2 true WO2011152689A2 (en) | 2011-12-08 |
| WO2011152689A9 WO2011152689A9 (en) | 2012-01-26 |
| WO2011152689A3 WO2011152689A3 (en) | 2012-04-19 |
Family
ID=45067210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2011/004103 WO2011152689A2 (en) | 2010-06-03 | 2011-06-03 | Method for purifying fucoxanthin derived from seaweed |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2011152689A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105997957A (en) * | 2016-07-08 | 2016-10-12 | 韩春超 | Fucoxanthine hydrogel patch for preventing and treating obesity |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050039283A (en) * | 2003-10-24 | 2005-04-29 | 목도창조 주식회사 | Extracting method of fucoxanthin using brown algae |
| EP1884238A1 (en) * | 2005-05-24 | 2008-02-06 | National University Corporation Hokkaido University | Agent having antiobesity activity and method of inhibiting obesity |
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| JP2008280281A (en) * | 2007-05-10 | 2008-11-20 | Hokkaido Univ | Antiobesitic active agent |
| WO2009048249A2 (en) * | 2007-10-10 | 2009-04-16 | Amicogen, Inc. | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
-
2011
- 2011-06-03 WO PCT/KR2011/004103 patent/WO2011152689A2/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050039283A (en) * | 2003-10-24 | 2005-04-29 | 목도창조 주식회사 | Extracting method of fucoxanthin using brown algae |
| EP1884238A1 (en) * | 2005-05-24 | 2008-02-06 | National University Corporation Hokkaido University | Agent having antiobesity activity and method of inhibiting obesity |
| US20080206275A1 (en) * | 2006-12-08 | 2008-08-28 | Zakir Ramazanov | Composition for treating obesity and method of using the same |
| US20080233209A1 (en) * | 2007-03-22 | 2008-09-25 | Polifenoles Naturales, Sl | Composition and method of use for the treatment of metabolic syndrome and inflammation |
| JP2008280281A (en) * | 2007-05-10 | 2008-11-20 | Hokkaido Univ | Antiobesitic active agent |
| WO2009048249A2 (en) * | 2007-10-10 | 2009-04-16 | Amicogen, Inc. | Composition for preventing or treating lipid metabolic disorders comprising fucoxanthin or marine plant extract containing same |
Non-Patent Citations (3)
| Title |
|---|
| H. MAEDA ET AL.: 'Fucoxanthin from edible seaweed, Undaria pinnatifida, shows antiobesity effect through UCPI expression in white adipose tissues' BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS vol. 332, 2005, pages 392 - 397 * |
| K. KANAZAWA ET AL.: 'Commercial-scale preparation ofbiofunctional fucoxanthin from waste parts of brown sea algae Laminaliajaponica' FOOD SCIENCE AND TECHNOLOGY RESEARCH vol. 14, no. 6, 2008, pages 573 - 582 * |
| M. WRONA ET AL.: 'Zeaxanthin in combination with ascorbic acid or alpha-tocopherol protects ARPE-19 cells against photosensitized peroxidation of lipids' FEE RADICAL BIOLOGY & MEDICINE vol. 36, no. 9, 2004, pages 1094 - 1101 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105997957A (en) * | 2016-07-08 | 2016-10-12 | 韩春超 | Fucoxanthine hydrogel patch for preventing and treating obesity |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011152689A3 (en) | 2012-04-19 |
| WO2011152689A9 (en) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | In vitro antioxidant activities of the polysaccharides from Pleurotus tuber-regium (Fr.) Sing. | |
| Chatzilazarou et al. | Removal of polyphenols from wine sludge using cloud point extraction | |
| CN103833692B (en) | Method for extracting high-purity fucoxanthin from seaweeds | |
| CN106720466A (en) | It is a kind of while the method for extracting high phospholipid krill oil and astaxanthin ester krill oil high | |
| CN102911138B (en) | The extracting and purifying method of fucoxanthin in a kind of brown alga | |
| CN103965143B (en) | A kind of method from marine unicellular diatom extraction and isolation fucoxanthin | |
| US20100152286A1 (en) | Method for Producing Fucoxanthin | |
| JP4571081B2 (en) | Lychee polyphenol-containing composition, production method and use thereof | |
| CN104045724B (en) | The method that Fuscoporia obliqua polysaccharide is prepared in extraction from Inonqqus obliquus | |
| KR102222043B1 (en) | Method of krill oil preparation and composition of krill oil | |
| JP5785101B2 (en) | How to prepare ajoene | |
| JP2008231198A (en) | Fucoxanthin-containing fat-soluble oil, method for producing the same, and method for producing fucoxanthin | |
| CN111548382A (en) | Method for extracting nicotinamide mononucleotide from avocado | |
| Li et al. | Research progress on polysaccharides from Ginkgo biloba | |
| KR20110119071A (en) | A preparative method for isolation of fucoxanthin from seaweeds by centrifugal partition chromatography | |
| WO2011152689A2 (en) | Method for purifying fucoxanthin derived from seaweed | |
| CN110713450A (en) | Astaxanthin extraction method based on haematococcus pluvialis | |
| RU2399298C1 (en) | Method of processing brown algae | |
| Kim et al. | Identification of 5-hydroxy-3, 6, 7, 8, 3, 4-hexamethoxyflavone from Hizikia fusiforme involved in the induction of the apoptosis mediators in human AGS carcinoma cells | |
| KR100526434B1 (en) | Extracting method of fucoxanthin using Brown Algae | |
| WO2011152692A2 (en) | Anti-obesity cream composition containing fucoxanthin | |
| WO2022215441A1 (en) | Novel polyphenol compound | |
| JP6108472B2 (en) | Grape rachis extract | |
| KR20110133000A (en) | A method for purifying fucoxanthin from seaweeds | |
| JP3967564B2 (en) | Lemon fermented product and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11790047 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11790047 Country of ref document: EP Kind code of ref document: A2 |